Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them

Claim 2

A taxane derivative of the formula ##STR16## wherein R 1 is phenyl or p-nitrophenyl, R 3 is furyl or thienyl, T 1 is hydrogen, hydroxyl protecting group, or --COT 2 , T 2 is H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl or monocylic aryl, Ac is acetyl, and E 1 and E 2 are independently selected from hydrogen and hydroxyl protecting groups.

Claim 3

A taxane derivative of the formula ##STR17## wherein R 1 is phenyl or p-nitrophenyl, R 3 is furyl or thienyl, T 1 is hydrogen, hydroxyl protecting group, or --COT 2 , T 2 is H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl or monocylic aryl, Ac is acetyl, and E 1 and E 2 are independently selected from hydrogen, and --COGCOR 1 wherein G is ethylene, propylene, CH═CH, 1,2-cyclohexane, or 1,2-phenylene, R 1 =OH base, NR 2 R 3 , OR 3 , SR 3 , OCH 2 CONR 4 R 5 , OH R 2 =hydrogen, methyl R 3 =(CH 2 ) n NR 6 R 7 ; (CH 2 ) n N.sup.⊕ R 6 R 7 R 8 X.sup.⊖ n=1 to 3 R 4 =hydrogen, lower alkyl containing 1 to 4 carbons R 5 =hydrogen, lower alkyl containing 1 to 4 carbons, benzyl, hydroxyethyl, CH 2 CO 2 H, dimethylaminoethyl R 6 R 7 =lower alkyl containing 1 or 2 carbons, benzyl or R 6 and R 7 together with the nitrogen atom of NR 6 R 7 form the following rings ##STR18## R 8 =lower alkyl containing 1 or 2 carbons, benzyl X.sup.⊖ =halide base=NH 3 , (HOC 2 H 4 ) 3 N, N(CH 3 ) 3 , CH 3 N(C 2 H 4 OH) 2 , NH 2 (CH 2 ) 6 NH 2 , N-methylglucamine, NaOH, KOH.

Claim 4

A taxane derivative of the formula ##STR17## wherein R 1 is phenyl or p-nitrophenyl, R 3 is furyl or thienyl, T 1 is hydrogen, hydroxyl protecting group, or --COT 2 , T 2 is H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl or monocylic aryl, Ac is acetyl, and E 1 and E 2 are independently selected from hydrogen, and --COGCOR 1 wherein G is ethylene, propylene, CH═CH, 1,2-cyclohexane, or 1,2-phenylene, R 1 =OH base, NR 2 R 3 , OR 3 , SR 3 , OCH 2 CONR 4 R 5 , OH R 2 =hydrogen, methyl R 3 =(CH 2 ) n NR 6 R 7 ; (CH 2 ) n N.sup.⊕ R 6 R 7 R 8 X.sup.⊖ n=1 to 3 R 4 =hydrogen, lower alkyl containing 1 to 4 carbons R 5 =hydrogen, lower alkyl containing 1 to 4 carbons, benzyl, hydroxyethyl, CH 2 CO 2 H, dimethylaminoethyl R 6 R 7 =lower alkyl containing 1 or 2 carbons, benzyl or R 6 and R 7 together with the nitrogen atom of NR 6 R 7 form the following rings ##STR18## R 8 =lower alkyl containing 1 or 2 carbons, benzyl X.sup.⊖ =halide base=NH 3 , (HOC 2 H 4 ) 3 N, N(CH 3 ) 3 , CH 3 N(C 2 H 4 OH) 2 , NH 2 (CH 2 ) 6 NH 2 , N-methylglucamine, NaOH, KOH.

Claim 5

The taxane derivative of claim 1 wherein T 1 is --COCH 3 , and E 1 and E 2 are hydrogen.

Claim 6

The taxane derivative of claim 1 wherein the taxane derivative has the 2'R, 3'S configuration.

Claim 7

A taxane derivative of the formula ##STR19## wherein Ph is phenyl, and Ac is acetyl.

Claim 8

A taxane derivative of the formula ##STR19## wherein Ph is phenyl, and Ac is acetyl.

Claim 9

A pharmaceutical composition which contains the taxane derivative of claim 1 and one or more pharmacologically acceptable, inert or physiologically active diluents or adjuvants.